瑞巴派特三联疗法用于胃溃疡伴胃出血的临床观察

发布时间：2018-04-11 11:42

本文选题：瑞巴派特 + 奥美拉唑　；参考：《中国药房》2017年06期

【摘要】：目的:观察瑞巴派特三联疗法用于胃溃疡伴胃出血的疗效和安全性。方法:130例胃溃疡伴胃出血患者随机分为对照组(65例)和观察组(65例)。对照组患者给予奥美拉唑肠溶胶囊20 mg,口服,每日2次+铝碳酸镁片500 mg,口服,每日1次;观察组患者在对照组治疗的基础上给予瑞巴派特片0.1 g,口服,每日3次。两组疗程均为12周。观察两组患者的临床疗效,嗳气、腹痛、腹胀、呕血/便血缓解时间,治疗前后临床症状评分,再出血发生情况及不良反应发生情况。结果:观察组患者近期总有效率显著高于对照组,临床症状与体征缓解时间均显著短于对照组,再出血发生率显著低于对照组,差异均有统计学意义(P0.05)。治疗前,两组患者临床症状评分比较,差异无统计学意义(P0.05)。治疗后,两组患者临床症状评分均显著低于同组治疗前,且观察组显著低于对照组,差异均有统计学意义(P0.05)。两组患者不良反应发生率比较,差异无统计学意义(P0.05)。结论:瑞巴派特三联疗法用于胃溃疡伴胃出血的近期疗效显著,可有效改善患者的消化道症状,降低再出血发生风险,且未增加不良反应的发生。
[Abstract]:Objective: to observe the curative effect and safety of triple therapy with rebapete for gastric ulcer with gastric hemorrhage.Methods 130 cases of gastric ulcer with gastric hemorrhage were randomly divided into control group (n = 65) and observation group (n = 65).The patients in the control group were given omeprazole enteric-coated capsule 20 mg orally twice a day, 500 mg twice a day, once a day, while the patients in the observation group were given repapet 0.1 g, 3 times a day, on the basis of the treatment in the control group.The course of treatment was 12 weeks in both groups.The clinical efficacy, belching, abdominal pain, abdominal distension, remission time of hematemesis / hematochezia, clinical symptom score, occurrence of rebleeding and adverse reactions were observed.Results: the short-term total effective rate in the observation group was significantly higher than that in the control group, the remission time of clinical symptoms and signs was significantly shorter than that in the control group, and the incidence of rebleeding was significantly lower than that in the control group (P 0.05).Before treatment, there was no significant difference in clinical symptom scores between the two groups (P 0.05).After treatment, the clinical symptom scores of the two groups were significantly lower than those of the same group before treatment, and the observation group was significantly lower than the control group, the difference was statistically significant (P 0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05).Conclusion: the short-term curative effect of the triple therapy of Rebapett for gastric ulcer with gastric hemorrhage is remarkable. It can effectively improve the digestive tract symptoms of the patients and reduce the risk of rebleeding without increasing the incidence of adverse reactions.
【作者单位】：三峡大学第一临床医学院/宜昌市中心人民医院胃肠外科;
【分类号】：R573.1

【参考文献】